|
17 Jun 2021 |
Gannex Announces Positive Topline Results of the U.S. Phase I Trial of NASH Drug ASC42, an FXR Agonist
|
|
17 Jun 2021 |
FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
|
|
17 Jun 2021 |
Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease
|
|
16 Jun 2021 |
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer
|
|
16 Jun 2021 |
REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2
|
|
16 Jun 2021 |
Mallinckrodt Announces U.S. FDA Approval of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat)
|
|
16 Jun 2021 |
Hugel America, Inc. Announces U.S. FDA Acceptance of Biologics License Application (BLA) for LetibotulinumtoxinA for Injection to Treat Glabellar (Frown) Lines
|
|
16 Jun 2021 |
Aqualung Therapeutics Plans A Phase 0 ARDS Trial for eNAMPT Monoclonal Antibody (Alt-100 mAb) Following Type B FDA Meeting
|
|
15 Jun 2021 |
Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion
|
|
15 Jun 2021 |
CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia
|
|
15 Jun 2021 |
Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434
|
|
15 Jun 2021 |
Innovent Announces First Overweight or Obese Subject Dosed in A Phase 2 Clinical Trial of IBI362 (a GLP-1 and Glucagon Receptor Dual Agonist) in China
|
|
15 Jun 2021 |
VectorY Raises €31 Million in Seed Financing to Develop Next-Generation Gene Therapies Aimed at Muscular and CNS Disorders
|
|
15 Jun 2021 |
Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
|
|
15 Jun 2021 |
Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19
|
|
15 Jun 2021 |
COVID-19 Vaccine AstraZeneca effective against Delta (‘Indian’) variant
|
|
15 Jun 2021 |
Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia
|
|
14 Jun 2021 |
EyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 Proof-of-Concept Ocular Surface Inflammation Study
|
|
14 Jun 2021 |
Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH
|
|
14 Jun 2021 |
RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis
|
